Leerink Partners Rates Rapport Therapeutics (RAPP) buy
Leerink Partners maintains a buy rating on Rapport Therapeutics with a $52 price target, a 29.81% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Leerink Partners rated Rapport Therapeutics, Inc. ($RAPP) "buy" with a $52 price target on June 24, 2026.
Since the rating, $RAPP is down 1.5% after 1 week, up 1.7% after 1 month and down 31.1% to date (from the $40 close on Jun 24, 2026).
RAPP
Rapport Therapeutics, Inc.
Key Points
- Leerink Partners reiterated its buy rating on Rapport Therapeutics, setting a $52 price target on June 24, 2026.
- Leerink Partners's $52 price target implies 29.81% upside from Rapport Therapeutics, Inc.'s ($RAPP) current $40.06 share price.
- Shares of NasdaqGM:RAPP traded near $40 on Friday, with a market cap of $1.86 billion and a 52-week high of $42.27.
- Rapport Therapeutics saw insider buying from multiple executives on June 10, 2026, with each purchasing 15,200 shares.
Get $RAPP trade alerts by text
We text you when insiders, Congress or big funds trade $RAPP. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Rapport Therapeutics, Inc. alert may contain errors. Disclosures
On June 24, 2026, Leerink Partners reiterated its buy rating on Rapport Therapeutics, Inc. (NasdaqGM:RAPP), setting a price target of $52. Analyst Marc Goodman reaffirmed his positive outlook on the stock, which is trading around $40.
Leerink Partners vs. the S&P 500
Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.
Rapport Therapeutics, Inc. Stock Down 1.0%
Shares of NasdaqGM:RAPP traded near $40 on Friday. Rapport Therapeutics has a market cap of approximately $1.86 billion. Despite not being currently profitable, the forward P/E ratio is not meaningful. The stock has a 52-week low of $11.05 and a high of $42.27. It has a 50-day moving average of $37.05 and a 200-day moving average of $30.30. The company maintains a strong financial position with a current ratio of 27.08 and a quick ratio of 26.64, and a debt-to-equity ratio of 2.29.
$RAPP price target
Rapport Therapeutics, Inc. daily closes and this analyst's $52 target. Not advice.
Other Institutional Activity in Rapport Therapeutics
Several institutional investors have adjusted their positions in Rapport Therapeutics. FMR LLC increased its holdings by 57,074 shares, ending with 7,168,939 shares valued at about $224.3 million, a 0.8% increase. TRV GP V, LLC held steady at 7,135,233 shares worth $223.3 million. ARCH VENTURE MANAGEMENT, LLC also maintained its position with 3,728,738 shares valued at $116.7 million. Meanwhile, Capital International Investors reduced its stake by 304,556 shares to 3,097,973 shares, valued at $96.9 million, a 9.0% decrease. Cormorant Asset Management, LP cut its holdings by 70,000 shares to 2,957,521 shares, valued at $92.5 million, a 2.3% decrease.
Insider Buying and Selling at Rapport Therapeutics, Inc.
On June 10, 2026, several insiders at Rapport Therapeutics purchased shares. John Maraganore, Paul Silva, Wendy Young, Ramiro Sanchez, James Healy, and Reid Huber each bought 15,200 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, Leerink Partners initiated coverage with a buy rating and a $52 price target. BTIG, on May 21, 2026, maintained its buy rating with a $65 target. Truist Securities assumed coverage with a buy rating and a $56 target on May 19, 2026. The consensus among analysts is a strong buy, with a target mean price of approximately $56.64 based on 11 analyst opinions.
About Rapport Therapeutics
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. Led by CEO Abraham N. Ceesay, the company focuses on developing small molecule medicines for central nervous system disorders. Its lead product candidate, RAP-219, targets focal epilepsy and other CNS disorders. The firm also works on treatments for chronic pain and hearing disorders. Founded in 2022, Rapport has 84 employees dedicated to advancing its innovative therapies.
Bottom Line
Rapport Therapeutics continues to attract attention with its promising pipeline and recent analyst endorsements. The reiterated buy rating from Leerink Partners underscores confidence in the company's growth prospects. Investors will be watching closely as the company progresses with its clinical developments.
Related Filing Alerts
Source: Leerink Partners's rating change on $RAPP (Jun 24, 2026). Written by software, not financial advice. How we make alerts